Bresat Cancer Update
Oncology Leader CommentarySpecial FeaturesPrevious Issues

Home: Oncology Leader Commentary: Gershon Locker, MD

Click on the topic below for comments by Dr Gershon Locker to comment on. You will also find links to related articles and clinical trials.

Trials of first line Arimidex
Choosing first-line endocrine therapy in postmenopausal patients
Vasomotor symptoms and Arimidex
Mechanisms of resistance to endocrine therapy
Tamoxifen rechallenge versus Arimidex
Aromatase inhibitors when adjuvant tamoxifen is contraindicated
ATAC adjuvant trial: Arimidex vs Tamoxifen vs the Combination

Aromatase inhibitors when adjuvant tamoxifen is contraindicated

Interview with Neil Love, MD from Breast Cancer Update for Medical Oncologists, Program 1 2000

Play Audio Below:

Dr. Locker: That question comes up, what if you have a woman who goes on tamoxifen and can’t tolerate it, or more commonly has heard that it’s a terrible drug, and she doesn’t want it. Would I put her in Arimidex? And the answer was until now, I never did. I basically tried to talk her into going on - staying on the tamoxifen. And I think now, if I really felt that she needed an adjuvant hormonal therapy and she was postmenopausal, she absolutely wouldn’t take tamoxifen - I would explain to her that there is no data in the adjuvant setting, the study is not yet reported, won’t be for a few years, but based on the metastatic setting I would be willing to give her anastrozole for five years. But she has to understand that this is an off-label use and all the side effects, etc, etc. But yes, I would do it. I am not sure that’s right, but I would do it.

Top of Page

Home · Contact us
Terms of use and general disclaimer